Patents by Inventor Jaspal Singh

Jaspal Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130085074
    Abstract: Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 4, 2013
    Applicant: Maxim Integrated Products, Inc.
    Inventors: Wynn L. WALKER, Michael L. Gallo, Xiao-Chi Jia, Keith Joho, Jaspal Singh Kang
  • Publication number: 20130034559
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed.
    Type: Application
    Filed: November 24, 2010
    Publication date: February 7, 2013
    Applicant: Medlmmune Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • Patent number: 8350011
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: January 8, 2013
    Assignee: MedImmune Limited
    Inventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang
  • Publication number: 20120328625
    Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
    Type: Application
    Filed: May 23, 2012
    Publication date: December 27, 2012
    Applicant: MEDIMMUNE, LLC
    Inventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
  • Publication number: 20120258495
    Abstract: Compositions and methods are disclosed for generating immunoglobulin structural diversity in vitro, and in particular, for reducing biases in V region and J segment gene utilization, and for generating immunoglobulin V-D-J recombination events in a manner that does not require D-J recombination to precede V-DJ recombination. Selection of advantageous combinations of immunoglobulin gene elements, including introduction of artificial diversity (D) segment genes and optimization of recombination signal sequence (RSS) efficiency, are disclosed.
    Type: Application
    Filed: August 8, 2011
    Publication date: October 11, 2012
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
  • Patent number: 8206936
    Abstract: Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: June 26, 2012
    Assignee: Amgen Inc.
    Inventors: Wynn L. Walker, Michael L. Gallo, Xiao-Chi Jia, Keith Joho, Jaspal Singh Kang
  • Patent number: 8207306
    Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: June 26, 2012
    Assignee: MedImmune, LLC
    Inventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
  • Publication number: 20120114667
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 10, 2012
    Applicant: MEDIMMUNE LIMITED
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
  • Publication number: 20120107324
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 3, 2012
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
  • Patent number: 8119130
    Abstract: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: February 21, 2012
    Assignee: MedImmune Limited
    Inventors: Simon Thomas Barry, Vahe Bedian, Bradley Hedberg, Jaspal Singh Kang, Qing Zhou
  • Publication number: 20110255359
    Abstract: An offset cancellation scheme for sense amplification is described. The scheme consists of group of transistors which are selectively coupled to high and low voltage levels via multi-phase timing. This results in a voltage level on nodes of interest which are a function of transistor mismatch. The resulting voltage levels act to compensates for the transistor mismatch, thereby improving the reliability of the sense amplifier in the presence of process non-idealities. The offset cancellation scheme is applicable to numerous types of sense amplifiers.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 20, 2011
    Inventors: Manoj Sachdev, Mohammad Sharifkhani, Jaspal Singh Shah, David Rennie
  • Patent number: 8012714
    Abstract: Compositions and methods are disclosed for generating immunoglobulin structural diversity in vitro, and in particular, for reducing biases in V region and J segment gene utilization, and for generating immunoglobulin V-D-J recombination events in a manner that does not require D-J recombination to precede V-DJ recombination. Selection of advantageous combinations of immunoglobulin gene elements, including introduction of artificial diversity (D) segment genes and optimization of recombination signal sequence (RSS) efficiency, are disclosed.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Innovative Targeting Solutions, Inc.
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
  • Patent number: 7968684
    Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: June 28, 2011
    Assignee: Abbott Laboratories
    Inventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
  • Publication number: 20110020360
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: February 18, 2010
    Publication date: January 27, 2011
    Applicant: ASTRAZENECA AB
    Inventors: NAOMI LAING, JASPAL SINGH KANG, IAN FOLTZ, GADI GAZIT-BOMSTEIN, XIAO-DANG YANG, SUE A. CARTLIDGE, DAVID CHARLES BLAKEY
  • Publication number: 20110021373
    Abstract: Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.
    Type: Application
    Filed: June 24, 2010
    Publication date: January 27, 2011
    Inventors: Wynn L. WALKER, Michael L. Gallo, Xiao-Chi Jia, Keith Joho, Jaspal Singh Kang
  • Publication number: 20100291088
    Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: July 26, 2010
    Publication date: November 18, 2010
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
  • Publication number: 20100260765
    Abstract: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
    Type: Application
    Filed: July 23, 2008
    Publication date: October 14, 2010
    Applicants: AstraZeneca AB, AstraZeneca UK Limited
    Inventors: Simon Thomas Barry, Vahe Bedian, Bradley Hedberg, Jaspal Singh Kang, Qing Zhou
  • Patent number: 7771951
    Abstract: Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: August 10, 2010
    Assignee: Amgen Fremont Inc.
    Inventors: Wynn L. Walker, Michael L. Gallo, Xiao-Chi Jia, Keith Joho, Jaspal Singh Kang
  • Publication number: 20100196388
    Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
    Type: Application
    Filed: September 18, 2009
    Publication date: August 5, 2010
    Applicant: Medlmmune LLC
    Inventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
  • Patent number: 7754859
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Charles Blakey, Sue A. Cartlidge